Tarsons Products Limited (NSE:TARSONS)
India · Delayed Price · Currency is INR 287.45
-12.05 (-4.02%)
Jul 17, 2026, 3:30 PM IST
Tarsons Products Revenue
In the fiscal year ending March 31, 2026, Tarsons Products had annual revenue of 4.23B INR with 7.67% growth. Tarsons Products had revenue of 1.21B in the quarter ending March 31, 2026, with 7.31% growth.
Revenue
4.23B
Revenue Growth
+7.67%
P/S Ratio
3.62
Revenue / Employee
4.66M
Employees
906
Market Cap
15.29B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 4.23B | 300.99M | 7.67% |
| Mar 31, 2025 | 3.92B | 960.20M | 32.40% |
| Mar 31, 2024 | 2.96B | 131.46M | 4.64% |
| Mar 31, 2023 | 2.83B | -175.46M | -5.83% |
| Mar 31, 2022 | 3.01B | 694.77M | 30.04% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 584.62B |
| Cipla | 278.28B |
| Apollo Hospitals Enterprise | 252.29B |
| Divi's Laboratories | 105.60B |
| Shalby | 11.41B |
| Windlas Biotech | 9.04B |
| Krsnaa Diagnostics | 7.99B |
| Ind-Swift Laboratories | 6.41B |